Showing results (1-10 of 60) with videos related to
Sort By:
Pageof 6
Hematology. American Society of Hematology. Education Program|December 13, 2012
How to use new biology to guide therapy in multiple myelomaGareth J Morgan, Martin F KaiserEjhaem|June 8, 2026
Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple MyelomaSina A Beer, Richard Houlston, Martin F KaiserBMC Cancer|November 8, 2017
Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case reportVallari Shah, Kevin D Boyd, Richard S Houlston, et al.Epigenomics|May 10, 2014
Current and potential epigenetic targets in multiple myelomaCharlotte Pawlyn, Martin F Kaiser, Faith E Davies, et al.Scientific Reports|July 26, 2022
Exploiting gene dependency to inform drug development for multiple myelomaMolly Went, Phuc H Hoang, Philip J Law, et al.European Journal of Haematology|January 15, 2013
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signallingMartin F Kaiser, Ulrike Heider, Maren Mieth, et al.The Journal of Molecular Diagnostics : JMD|July 1, 2020
High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in Vitro ResearchKaren Menezes, Lilit Atanesyan, Amy L Sherborne, et al.Blood Cancer Journal|April 8, 2025
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancySina A Beer, Molly Went, Charlie Mills, et al.European Radiology|November 15, 2017
Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRIJessica M Winfield, Gabriele Poillucci, Matthew D Blackledge, et al.Blood Neoplasia|March 20, 2026
Proteome-wide Mendelian randomization identifies protein associations and therapeutic targets for B-cell malignancyMolly Went, Charlie Mills, Amit Sud, et al.Pageof 6